Document is current
Any future updates will be listed below
-
Authors
Silginer, Manuela
Weller, Michael
Stupp, Roger
Roth, Patrick
- License Information
-
More Information
Article History
Received: 23 December 2016
Revised: 6 March 2017
Accepted: 8 March 2017
First Online: 20 April 2017
Competing interests
: MW has received research grants from Actelion, Alpinia Institute, Bayer, Isarna, MSD, Merck Serono, Piqur and Roche and honoraria for lectures or advisory board participation from Celldex, Isarna, Magforce, MSD, Merck Serono, Pfizer, Roche and Teva. RS is the principal investigator for the pivotal clinical trials on TTFields in newly diagnosed and recurrent glioblastoma. RS served as an advisor to Novocure (non-remunerated), and has received travel assistance for trial associated activities, data review and data presentation at scientific meetings. PR has received honoraria for advisory boards and lectures from BMS, Roche, MSD, Novartis and Molecular Partners. MS declares no conflict of interest.
